Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.45 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HRH2 | P25021 | 1/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL86666 | 1.00 | LMNA (0.47) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL143674 | 1.00 | LMNA (0.47) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL4809535 | 0.97 | LMNA (0.43) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL345694 | 0.93 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL345693 | 0.93 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL2186144 | 0.93 | GPR119 (0.44) | LMNANPSR1KMT2AMEN1MMP13 | |
| SCHEMBL29285446 | 0.91 | LMNA (0.45) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL4093277 | 0.90 | NPSR1 (0.44) | LMNANPSR1KMT2AMEN1APP | |
| SCHEMBL7918528 | 0.89 | HCRTR2 (0.49) | KMT2AMEN1APPHTR1AADRA2A | |
| SCHEMBL7918530 | 0.89 | HCRTR2 (0.49) | KMT2AMEN1APPHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Redona Therapeutics, Inc. | 2024-08-01 | — | — | US | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-4114831-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | Twentyeight-Seven, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| WO-2022165530-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | AUTOIMMUNE PHARMA LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | ZAFGEN, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3334728-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2018-06-20 | — | — | EP | disclosed |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | DECODE CHEMISTRY, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBVIE INC. | 2004-12-23 | — | — | US | disclosed |
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | ABBOTT LABORATORIES | 2004-09-02 | — | — | US | disclosed |
| US-6562808-B1 | Calcium channel antagonists effective in treating intestinal diseases caused by abnormal acceleration of the contraction of intestinal tracts such as irritable bowel syndrome, without significant cardiac effects | AJINOMOTO CO., INC. (JP) | 2003-05-13 | — | — | US | disclosed |
| EP-1020466-B1 | 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME | AJINOMOTO KK (JP) | 2003-02-19 | — | — | EP | disclosed |
| EP-1020466-A1 | 5,11-DIHYDRODIBENZ[b,e][1,4]OXAZEPINE DERIVATIVES AND MEDICINAL COMPOSITION CONTAINING THE SAME | Ajinomoto Co., Inc. (JP) | 2000-07-19 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| US-4902684-A | Benzazepine and benzothiazepine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1989012633-A1 | BENZAZEPINE AND BENZOTHIAZEPINE DERIVATIVES | E.R. SQUIBB & SONS, INC. (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171845-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | LMNA 3055/4885NPSR1 1278/4885KMT2A 408/4885 |
| US-20190084969-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | LMNA 3216/4885NPSR1 3390/4885KMT2A 1027/4885 |
| US-20190084968-A1 | FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME | METAP2, FAP, FOLH1 | LMNA 3216/4885NPSR1 3390/4885KMT2A 1027/4885 |
| US-20070066820-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LMNA 1522/4885NPSR1 752/4885KMT2A 3243/4885 |
| US-20070078263-A1 | BIARYL SUBSTITUTED HETEROCYCLE INHIBITORS OF LTA4H FOR TREATING INFLAMMATION | LTA4H, LTB4R, LTC4S | LMNA 1522/4885NPSR1 752/4885KMT2A 3243/4885 |
| US-20200147064-A1 | Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor | LTB4R, LTC4S, LTB4R2 | LMNA 315/4885NPSR1 1064/4885KMT2A 3725/4885 |
| US-20040260100-A1 | Process for preparing 2-methylpyrrolidine and specific enantiomers thereof | QDPR, PNMT, MTAP | LMNA 3055/4885NPSR1 1278/4885KMT2A 408/4885 |
| US-10023561-B2 | Fumagillol heterocyclic compounds and methods of making and using same | METAP2, FAP, FOLH1 | LMNA 3216/4885NPSR1 3390/4885KMT2A 1027/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | LMNA 2773/4885NPSR1 3858/4885KMT2A 2659/4885 |
| US-20240254136-A1 | COMPOUNDS TARGETING RNA-BINDING PROTEINS OR RNA-MODIFYING PROTEINS | NSUN3, NSUN2, RBM3 | LMNA 1072/4885NPSR1 3301/4885KMT2A 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.